Clinical Trial

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 20, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-29; most recent amendment 2025-07-18.
Status change: Not Yet Recruiting → Recruiting 2025-07-18
Trial Details
NCT Number NCT06666270
Lead Sponsor Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Conditions Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, Prostate Cancer, BRCA Mutation, HRR Deficiency
Enrollment 30 participants
Start Date 2024-11-21
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-20